Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

NCT01009593 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1035

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description

Conditions

Hepatocellular Carcinoma Non-resectable
Hepatocellular Carcinoma Recurrent
Carcinoma, Hepatocellular
Liver Diseases
Neoplasms by Histologic Type
Digestive System Neoplasms
Carcinoma
Liver Neoplasms
Neoplasms
Neoplasms by Site
Digestive System Diseases
Adenocarcinoma
Neoplasms, Glandular and Epithelial

Interventions

DRUG: ABT-869
DRUG: Sorafenib

Sponsor

Abbott